Company intelligence / Profile preview

Diamune Therapeutics

Beverly, Massachusetts, United Stateslinkedin.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Diamune Therapeutics was spun out of Akston Biosciences in August 2023 to focus on developing innovative IgG Fc-Fusion insulin analogs designed to mitigate and prevent autoimmune diabetes. The company leverages the proprietary Ambifect™ Fc-fusion protein platform originally developed at Akston. While specific clinical results are not yet published, the company’s technology has been granted patents for ultra-long acting insulins and candidates aimed at delaying or preventing autoimmune diabetes. Manufacturing capabilities are supported by facilities inherited from Akston Biosciences.

Therapeutic areas
Endocrinology
Modalities
Protein therapeuticsFc-fusion proteinsInsulin analogs
Industry
Biotech
02

Drug pipeline

2 assets

AKS-107

Preclinical

1 more asset in the full pipeline.

Request access →
03

Partnerships

No external partnerships disclosed for Diamune specifically as of May 2025; parent company has licensed related veterinary insulins to Dechra Pharmaceuticals PLC.

Beyond the preview

Go deeper on Diamune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamune Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call